Cross Staff Investments Inc Buys New Stake in Stryker Corporation $SYK

Cross Staff Investments Inc bought a new stake in Stryker Corporation (NYSE:SYK) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 508 shares of the medical technology company’s stock, valued at approximately $201,000.

Other institutional investors have also bought and sold shares of the company. Sachetta LLC raised its position in shares of Stryker by 58.7% during the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after buying an additional 27 shares in the last quarter. Goodman Advisory Group LLC bought a new stake in Stryker during the first quarter worth approximately $32,000. Ridgewood Investments LLC increased its stake in Stryker by 48.4% during the second quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock worth $36,000 after acquiring an additional 30 shares during the last quarter. Ransom Advisory Ltd bought a new stake in Stryker during the first quarter worth approximately $37,000. Finally, Smallwood Wealth Investment Management LLC purchased a new position in shares of Stryker in the 1st quarter worth approximately $40,000. Institutional investors own 77.09% of the company’s stock.

Analysts Set New Price Targets

SYK has been the subject of a number of analyst reports. Wall Street Zen downgraded Stryker from a “buy” rating to a “hold” rating in a research report on Friday, September 26th. Rothschild Redb raised shares of Stryker to a “hold” rating in a research note on Thursday, September 18th. Needham & Company LLC increased their target price on shares of Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Weiss Ratings reiterated a “buy (b-)” rating on shares of Stryker in a report on Wednesday. Finally, Redburn Partners set a $420.00 target price on Stryker in a research report on Thursday, September 18th. Fifteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $430.10.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the transaction, the director owned 3,222,108 shares of the company’s stock, valued at $1,212,962,556.60. The trade was a 5.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Viju Menon sold 500 shares of Stryker stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the transaction, the insider directly owned 12,511 shares in the company, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

Stryker Price Performance

Stryker stock opened at $364.77 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The stock has a market cap of $139.46 billion, a price-to-earnings ratio of 48.31, a price-to-earnings-growth ratio of 2.67 and a beta of 0.94. The firm has a 50-day moving average of $380.25 and a two-hundred day moving average of $378.75. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.07 by $0.06. The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.Stryker’s quarterly revenue was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, research analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. Stryker’s dividend payout ratio is presently 44.50%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.